Cargando…
Multiple Autoimmune Complications After a Single Dose of Pembrolizumab
Pembrolizumab, a monoclonal antibody that inhibits programmed cell death protein-1 (PD-1), is an important treatment for various malignancies. Unfortunately, it has also been associated with a wide array of immune-related adverse events. We present a unique case of a patient who received a single do...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Cureus
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10079282/ https://www.ncbi.nlm.nih.gov/pubmed/37033516 http://dx.doi.org/10.7759/cureus.35871 |